Capricor Therapeutics Inc CAPR

Healthcare Biotechnology

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

NDAQ:CAPR - Post by User

Capricor Therapeutics Inc

Bullboard Posts

Post by fibonnacion Apr 21, 2020 3:33pm

176 Views

Post# 30935656

capr share price keep creeping up....

even in this tuff market which is a bullish sign

capr has several irons in fire but biggest is the us govt using its drug to treat corona

testing is underway and will have results in a couple weeks

any hint that it is helping the patients (the first 2 were seriously sicj and both recovered) and this stock hits 10-20$ instantly

glta

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features